All articles tagged with #crinetics
Vertex will spend $10 billion to acquire Crinetics Pharmaceuticals, its largest-ever deal, expanding Vertex's portfolio in rare endocrine disorder therapies and signaling a major strategic move in biotech mergers and acquisitions.
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals, picking up Crinetics’ approved drug Palsonify for acromegaly and additional late-stage candidates, including a therapy for congenital adrenal hyperplasia; Crinetics stock surged after hours, and the deal stands as Vertex’s largest acquisition amid a biotech M&A boom.